Montara Therapeutics Lands $8M for Brain-Only Drug Development

Written By REQ

Seed round led by SV Health and Two Bear Capital will fund approach aiming to tackle dose-limiting side effects in neurological treatments.

Montara Therapeutics, a biopharmaceutical company focused on developing safer and more effective neuroscience drugs, has announced it has closed its $8 million seed round. The financing, which was led by SV Health Investors’ Dementia Discovery Fund and co-led by Two Bear Capital, also saw participation from Dolby Family Ventures and KdT Ventures. The funds will support the advancement of Montara’s BrainOnly platform, a technology designed to mitigate peripheral side effects by concentrating drug activity exclusively within the brain.

Read the full story from Longevity.Technology here:

https://longevity.technology/news/montara-therapeutics-lands-8m-for-brain-only-drug-development/

REQ

REQ offers award-winning digital marketing solutions for the branded world. Browse our selection of case studies for globally recognized brands like eBay and Amazon.

https://req.co/
Previous

Talus Bio tacks on $11M to target hard-to-reach transcription factors
Next

Binarly Raises $10.5 Million in Seed Round